Department of Plastic and Reconstructive Surgery, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Plastic and Reconstructive Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Oxid Med Cell Longev. 2022 Aug 4;2022:4156966. doi: 10.1155/2022/4156966. eCollection 2022.
Head and neck squamous carcinoma (HNSC) is the most prevalent malignancy of the head and neck regions. Long noncoding RNAs (lncRNAs) are vital in tumorigenesis regulation. However, the role of lncRNAs in HNSC requires further exploration. Herein, through bioinformatic assays using The Cancer Genome Atlas (TCGA) datasets, rapid amplification of cDNA ends (RACE) assays, and RNA-FISH, we revealed that a novel cytoplasmic transcript, HNSC-associated transcript 1 (HNSCAT1, previously recognized as linc01269), was downregulated in tumor samples and advanced tumor stages and was also associated with favorable outcomes in HNSC. Overexpression of HNSCAT1 triggered treatment efficacy in HNSCs both and . More importantly, through high-throughput transcriptome analysis (RNA-seq, in NODE database, OEZ007550), we identified KRT80, a tumor suppressor in HNSC, as the target of HNSCAT1. KRT80 expression was modulated by lncRNA HNSCAT1 and presented a positive correlation in tumor samples ( = 0.52, < 0.001). Intriguingly, we identified that miR-1245 simultaneously interacts with KRT80 and HNSCAT1, which bridges the regulatory function between KRT80 and HNSCAT1. Conclusively, our study demonstrated that lncRNA HNSCAT1 functions as a necessary tumor inhibitor in HNSC, which provides a novel mechanism of lncRNA function and provides alternative targets for the diagnosis and treatment of HNSC.
头颈部鳞状细胞癌(HNSC)是头颈部最常见的恶性肿瘤。长链非编码 RNA(lncRNA)在肿瘤发生调控中起着重要作用。然而,lncRNA 在 HNSC 中的作用需要进一步探索。在此,我们通过使用癌症基因组图谱(TCGA)数据集的生物信息学分析、快速扩增 cDNA 末端(RACE)分析和 RNA-FISH,揭示了一种新型细胞质转录本 HNSC 相关转录本 1(HNSCAT1,以前被认为是 linc01269)在肿瘤样本和晚期肿瘤阶段下调,并且与 HNSC 的良好预后相关。HNSCAT1 的过表达在 HNSC 中触发了治疗效果,无论是在体内还是体外。更重要的是,通过高通量转录组分析(RNA-seq,在 NODE 数据库,OEZ007550),我们鉴定出 KRT80,一种 HNSC 中的肿瘤抑制因子,是 HNSCAT1 的靶标。KRT80 的表达受 lncRNA HNSCAT1 调节,在肿瘤样本中呈正相关(=0.52,<0.001)。有趣的是,我们发现 miR-1245 同时与 KRT80 和 HNSCAT1 相互作用,这架起了 KRT80 和 HNSCAT1 之间调节功能的桥梁。总之,我们的研究表明 lncRNA HNSCAT1 是 HNSC 中一种必要的肿瘤抑制剂,为 lncRNA 功能提供了一种新的机制,并为 HNSC 的诊断和治疗提供了替代靶点。